![]() |
市場調查報告書
商品編碼
2016090
無細胞蛋白表達市場報告:按產品、方法、應用、最終用戶和地區分類(2026-2034 年)Cell-free Protein Expression Market Report by Product, Method, Application, End User, and Region 2026-2034 |
||||||
2025年,全球無細胞蛋白表現市場規模達3.019億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到5.301億美元,2026年至2034年的複合年成長率(CAGR)為6.26%。該市場正經歷顯著成長,主要得益於個人化醫療、疫苗研發和合成生物學領域的進步。製藥和生物技術領域對經濟高效且靈活的解決方案的需求不斷成長,進一步推動了市場成長,使無細胞蛋白質表現(CFPE)成為該行業的關鍵驅動力。
無細胞蛋白表現(CFPE)是指利用從細胞中提取的生物分子翻譯機制,在溶液中產生目標重組蛋白。這可以透過各種細胞裂解液(例如大腸桿菌、兔網網狀紅血球、小麥胚芽、昆蟲細胞和哺乳動物細胞的裂解液)的無細胞蛋白質表現系統來實現。 CFPE廣泛應用於酵素工程、蛋白質標記、蛋白質純化、蛋白質-蛋白質交互作用以及高通量突變體生產等領域。此外,CFPE也用於分析蛋白質穩定性、分解和折疊所需的關鍵組件。與基於細胞的蛋白質表現相比,無細胞蛋白質表現更省時、更便捷,允許引入非天然氨基酸,並能提高蛋白的穩定性和特異性。
合成生物學中的應用
無細胞蛋白表現(CFPE)已成為合成生物學中的關鍵工具,使科學家能夠更精確地設計和建構複雜的生物系統。這些平台有助於基因迴路的快速原型製作,從而在不受活細胞限制的情況下促進快速迭代和最佳化。 CFPE 也支持複雜生物合成途徑的檢驗,加速開發用於生產有用化合物的新型代謝途徑。此外,在可控的模組化環境中建構和修飾具有特定功能的蛋白質的能力,增強了合成生物學專案的創新性和多功能性。這種速度和柔軟性的結合對於研發和前沿生物技術應用的發展至關重要。合成生物學技術的進步正在顯著推動無細胞蛋白質表現市場的成長。
在蛋白質工程和藥物發現領域的應用不斷擴展
無細胞系統在蛋白質工程和藥物研發領域的日益普及正在改變製藥業。這些系統能夠快速、高通量地篩檢蛋白質變體,從而加速發現最佳候選藥物。透過消除活細胞的限制,無細胞蛋白質工程(CFPE)能夠生產難以處理的蛋白質,例如膜結合蛋白或毒性蛋白,這些蛋白在傳統系統中難以表現。這種能力加速了新型疫苗和生物製藥的研發,並實現了蛋白質結構的精確修飾和最佳化。此外,無細胞平台簡化了迭代式設計-建造-測試週期,顯著縮短了研發時間和成本。因此,Nuclear公司於2024年10月成功資金籌措了7,500萬美元,用於其eProtein Discovery™系統的商業化。該系統能夠簡化藥物研發中的蛋白質表現和純化流程。這筆Elevage Medical Technologies主導的資金籌措旨在提高研究實驗室的蛋白質生產效率,將研發週期從數月大幅縮短至48小時以內。隨著創新技術和大量投資推動 CFPE 系統在整個製藥行業的成長和應用,這些進步有望擴大無細胞蛋白質表現 (CFPE) 的市場佔有率。
擴大疫苗生產
新冠肺炎疫情凸顯了對快速疫苗生產的需求,也凸顯了無細胞蛋白表現(CFPE)平台的顯著優勢。 CFPE系統能夠高效合成重組蛋白和mRNA疫苗,無需活細胞培養,加速候選疫苗的研發。這縮短了從設計到生產的時間,使疫苗能夠快速應對新出現的感染疾病。例如,2024年10月,LenioBio宣布與ReciBioPharm合作,利用其蛋白質表現技術提升疫苗產量。此次合作旨在根據流行病防範創新聯盟(CEPI)的「百日計畫」擴大蛋白生產規模,加速疫苗研發。此外,CFPE具有擴充性和柔軟性,能夠輕鬆調整產量以滿足需求。隨著新病原體的出現和對不同類型疫苗需求的增加,CFPE快速生成和修飾疫苗組分的能力確保了穩健且適應性強的生產流程,這對全球公共衛生舉措至關重要。這些進步和策略合作為全球無細胞蛋白表達市場帶來了光明的前景。
The global cell-free protein expression market size reached USD 301.9 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 530.1 Million by 2034, exhibiting a growth rate (CAGR) of 6.26% during 2026-2034. The market is experiencing significant growth mainly driven by advancements in personalized medicine, vaccine development, and synthetic biology. The rising demand for cost-effective, flexible solutions in pharmaceuticals and biotechnology further propels market growth, positioning CFPE as a key industry enabler.
Cell-free protein expression (CFPE) refers to the production of desired recombinant proteins in solution using biomolecular translation machinery extracted from cells. It can be carried out using different cell lysates, such as E. coli, rabbit reticulocytes, wheat germ, insect cells, and mammalian cell-free protein expression systems. They are widely used in enzyme engineering, protein labeling, protein purification, protein-protein interaction, and high throughput production of mutants. CFPE is also used for analyzing components needed for protein stability, degradation, and folding. As compared to cell-based protein expression, cell-free protein expression is time efficient and convenient, allows the incorporation of non-natural amino acids, and provides enhanced stability and specificity.
Adoption in Synthetic Biology
Cell-Free Protein Expression (CFPE) has become a pivotal tool in synthetic biology, enabling scientists to design and engineer complex biological systems with enhanced precision. These platforms allow for the rapid prototyping of genetic circuits, facilitating swift iterations and optimizations without the limitations of living cells. CFPE also supports the testing of intricate biosynthetic pathways, accelerating the development of novel metabolic routes for producing valuable compounds. Furthermore, the ability to create and modify proteins with specific functionalities in a controlled, modular environment enhances innovation and versatility in synthetic biology projects. This combination of speed and flexibility is crucial for advancing research and developing cutting-edge biotechnological applications. Advancements in synthetic biology technologies are contributing significantly to the cell-free protein expression market growth.
Increased Use in Protein Engineering and Drug Development
The rising use of cell-free systems in protein engineering and drug development is transforming the pharmaceutical landscape. These systems enable rapid, high-throughput screening of protein variants, accelerating the identification of optimal therapeutic candidates. By eliminating the constraints of living cells, CFPE facilitates the production of challenging proteins, such as membrane-bound or toxic proteins, which are often difficult to express in traditional systems. This capability enhances the development of novel vaccines and biologics, allowing for precise modifications and optimization of protein structures. Additionally, cell-free platforms streamline the iterative design-build-test cycles, significantly reducing development time and costs. In line with this, in October 2024, Nuclera secured $75 million to commercialize its eProtein Discovery(TM) system, streamlining protein expression and purification for drug discovery. The funding, led by Elevage Medical Technologies, aims to enhance protein production efficiency in research labs, significantly reducing timelines from months to under 48 hours. These advancements are set to increase cell-free protein expression market share, as innovative technologies and substantial investments drive the growth and adoption of CFPE systems across the pharmaceutical industry.
Expansion in Vaccine Production
The demand for rapid vaccine production, particularly highlighted during the COVID-19 pandemic, underscores the significant advantages of Cell-Free Protein Expression (CFPE) platforms. CFPE systems facilitate the swift development of vaccine candidates by enabling the efficient synthesis of recombinant proteins and mRNA-based vaccines without the constraints of living cell cultures. This accelerates the timeline from design to production, allowing for quicker responses to emerging infectious diseases. For instance, in October 2024, LenioBio announced its partnership with ReciBioPharm to enhance vaccine production using its protein expression technology. This collaboration aims to scale up protein manufacturing, aligning with CEPI's 100 Days Mission to expedite vaccine development. Additionally, CFPE offers scalability and flexibility, making it easier to adjust production volumes based on demand. As new pathogens arise and the need for diverse vaccine types grows, CFPE's ability to rapidly generate and modify vaccine components ensures a robust and adaptable manufacturing process, essential for global public health initiatives. These advancements and strategic collaborations are creating a positive cell-free protein expression market outlook across the globe.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.